ArticleAesthetic plastic surgery2026
The Impact of Tranexamic Acid Administration Route on Outcomes in Reduction Mammaplasty.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative hematoma requiring unplanned intervention remains a clinically significant complication following reduction mammaplasty. Tranexamic acid (TXA) is increasingly used to reduce its occurrence and perioperative bleeding, but the optimal route of administration in breast reduction surgery remains unclear.
objectivesThis study aimed to evaluate the effects of different TXA administration routes on hematoma incidence and perioperative outcomes in patients undergoing reduction mammaplasty.
methodsWe conducted a retrospective cohort study of consecutive patients who underwent bilateral reduction mammaplasty at a single institution between 2020 and 2024. Patients were stratified into three groups according to the route of TXA administration: intravenous, topical, or combined intravenous plus topical. Group differences were evaluated using univariate analyses and multivariable logistic regression.
resultsA total of 272 patients were included. The incidence of postoperative hematoma requiring intervention was low (0.0-2.4%) and did not differ significantly between groups. Estimated intraoperative blood loss was significantly higher in the intravenous TXA group (p = 0.004). Partial or total nipple-areolar complex necrosis occurred more frequently in the combined TXA group (7.7%; p = 0.056 overall, with pairwise p = 0.013 compared to other groups). In multivariable analysis, comorbidity burden showed a trend toward predicting postoperative hematoma.
conclusionsThe route of TXA administration did not significantly affect hematoma rates. Although a higher incidence of nipple-areolar complex necrosis was observed in the combined TXA group, this finding is based on a small number of events and should be interpreted with caution. Prospective studies are needed to further evaluate the optimal TXA administration strategy in reduction mammaplasty. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42864535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.